Silvercrest Asset Management Group LLC Protagonist Therapeutics, Inc Transaction History
Silvercrest Asset Management Group LLC
- $14.6 Billion
- Q2 2025
A detailed history of Silvercrest Asset Management Group LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 54,723 shares of PTGX stock, worth $4.17 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
54,723
Previous 54,723
-0.0%
Holding current value
$4.17 Million
Previous $2.65 Million
14.29%
% of portfolio
0.02%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding PTGX
# of Institutions
296Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$470 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$439 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$438 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$332 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$247 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.74B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...